Again FDA emphasises Importance of written Contracts
Recommendation
10/11 February 2026
Heidelberg, Germany
Medicinal Products/Drugs meet Medical Devices
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
End 2016, the US Food and & Administration (FDA) published its long awaited final Guidance on Contract Manufacturer Quality Agreements.
The authority recommends that quality agreements should contain the following sections at a minimum:
- purpose and scope of the agreement
- terms of the agreement, including its effective dates
- terms for dispute resolution
- responsibility of each respective party
- change control and revision practices
And the agency takes things seriously. In a recent Warning Letter from March 2018, the FDA again refers to Quality Agreements and the respective guidance: "FDA is aware that many pharmaceutical product manufacturers use independent contractors, such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer." In their relationship with a customer, they recommend the addressee (Tris Pharma Inc.), to have a look at FDA's guidance document.
For further information please see the FDA Warning Letter to Tris Pharma Inc.
Related GMP News
04.02.2026When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025
27.01.2026New Ph. Eur. Publication Schedule
21.01.2026EU Pharma Package: EMA with single Point of Information
14.01.2026European QP Association Developments September through December 2025
14.01.2026Could a change of ownership be relevant to GMP?
07.01.2026Is QP Certification required when Products do not enter EU Territory?